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Background. Treatment of patients who need coronary revascularization before undelayable non-cardiac surgery is challenging.
Methods. We assessed the safety and eﬃcacy of percutaneous coronary interventions (PCI) using the AvantgardeTM Carbostent
(CID, Italy) in patients undergoing PCI before undelayable non-cardiac surgery. The Multiplate analyzer point-of-care was used to
assess residual platelet reactivity. One major cardiac events (MACE, deﬁned as death, myocardial infarction, and stent thrombosis
and major bleeding) were assessed. Results. 42 consecutive patients were analyzed. Total stent length ≥25mm was observed in 16
(37%) patients. Multivessel stenting was performed in 11 (31.5%) patients. Clopidogrel was interrupted 5 days before surgery in
35 patients, whereas it was stopped the day of the surgery in 7 patients. Surgery was performed after 27 ±9 (7–42) days from PCI.
MACE occurred in one patient (2.4%; 95% conﬁdence interval: 0.01–13%), who had fatal acute myocardial infarction 3 days after
abdominal aortic aneurysm surgery and 12 days after stent implantation. No case of major bleeding in the postoperative phase
was observed. Conclusions. The present pilot study suggests that, although at least 10–14 days of dual antiplatelet therapy remain
mandatory, the AvantgardeTM stent seems to have a role in patients requiring undelayable surgery.
1.Introduction
Decision-making for high cardiovascular risk patients re-
quiring undelayable surgical procedure is still challenging.
Undelayable surgery may be necessary in patients suﬀering
frommalignancy,highruptureriskaneurismaldisease,acute
abdominal disease, and pharmacological uncontrolled pain
duetoorthopedicorneurologicaldisease.Thecurrentguide-
linesareveryrestrictivetotheprophylacticmyocardialrevas-
cularization before noncardiac surgery [1]. In this condition
percutaneous coronary revascularization (PCI) should be
preferredtocoronaryarterybypasssurgery(CABG)[1].Due
to the need for dual antiplatelet therapy (DAPT), the current
guidelines recommend to delay surgery until after the time
window required for DAPT, that is 30 days for bare-metal
stents(BMSs)and1yearfordrug-elutingstent[1].However,
the 30-day DAPT may represent an unacceptable delay for
some patient scheduled for undeferrable noncardiac surgery.
In this challenging scenario, the risk of major cardiac event,
due the severe coronary artery disease, should be balanced
to the risk of stent thrombosis, associated with premature
DAPT discontinuation. The reported rate of stent thrombo-
sis in this setting ranges from 4% to more than 50% [2–5].
Stent thrombosis seems to be caused by the premature dis-
continuation or reduction of DAPT, the thrombotic risk as-
sociated with many forms of major surgery, or an interaction
between the two.
New stent types, allowing more rapid reendothelializa-
tion, may minimize the risk of stent thrombosis [6]. The
AvantgardeCarbostent(CID,Saluggia,Italy)mightrepresent
a further solution. This new stent combines the unique char-
acteristics of the Carbostent family (integral Carboﬁlm coat-
ing, close cell design) with a thinner and optimized stent
strut, which has an impact on the rapidity of the endothe-
lializationprocess,reducingtheriskofthrombosisandsafety
issues.
Therefore, we investigated the clinical performance, eﬃ-
cacy, and the complication rate of this new device in a pilot
study of consecutive patients with indication for percuta-
neous coronary interventions before undeferrable noncar-
diac surgery.2 Thrombosis
2. Matherials andMethods
2.1. Patients Population. All consecutive patients requiring
coronaryrevascularizationbeforeanundelayablemajornon-
cardiac surgery in our Institution from October 2009 to Sep-
tember2011wereincludedinthepresentstudy.Patientswere
candidate for coronary revascularization before noncardiac
surgery only if they fulﬁlled the following criteria: (a) pa-
tients with unstable angina or acutecoronarysyndromes, (b)
stablepatientswithleftmaindiseaseorthreevesseldiseaseor
2-vessel disease with proximal left anterior descending artery
disease and either left ventricular ejection fraction <50% or
inducible ischemia, and (c) stable patients non controlled
with optimal medical therapy [7]. All patients were treated
by PCI. The surgical procedures were categorized according
to the surgical risk, based on the Revised Cardiac Risk Index
[8].Theriskofnoncardiacsurgerywasdeﬁnedhighandlow.
High risk included abdominal, vascular, thoracic, and head
and neck; low risk included urologic, orthopedic, breast, and
skin [9].
2.2. Percutaneous Coronary Intervention and Noncardiac Sur-
gery. Patients received intracoronary isosorbide dinitrate
(0.1–0.3-mg) prior to initial and ﬁnal angiograms to achieve
maximal vasodilatation Percutaneous coronary intervention
was performed by implantation of a Avantgarde stent (CID,
Saluggia, Italy) in all instances. Stents were implanted ac-
cording to current clinical practice. Direct stenting was per-
formed according to the operator’s preference. All patients
received aspirin 325mg and clopidogrel (75mg daily) before
stent deployment, with a loading dose (600mg of clopido-
grel) given to patients not pretreated. All patients received
unfractionatedheparin(70IU/Kg)orbivalurdin(0.75mg/kg
prior to the start of the intervention, followed by infusion of
1.75mg/kg per hour or 1.0mg/kg per hours in patients with
chronic kidney disease for the duration of the procedure) in
order to achieve and activated clotting time >250 seconds.
Glycoprotein IIb/IIIa inhibitors were administered according
to operator preference.
2.3. Point-of-Care Platelet Function Testing. The ADP-in-
duced platelet aggregation in whole blood was assessed with-
in 24 hours after stent implantation with multiple electrode
platelet aggregometry (MEA) using a new-generation impe-
dance aggregometer called Multiplate analyzer (Dynabyte)
[10, 11]. After 1:2 dilution of whole blood with 0.9% NaCl
solution and stirring for 3min in the test cuvettes at 37◦C,
6.4µmol/L ADP was added. Platelet aggregation was contin-
uously recorded for 5min. Impedance with MEA is trans-
formed to arbitrary aggregation units (AUs) that are plotted
against time (AU·min). According to the AU·min value,
the following groups were identiﬁed: enhanced responders
(≤188AU·min), low responders (≥468AU·min), and nor-
mal responders (189 to 467AU·min) [10, 11]. Although not
supported by previous studies, these values were used to
guidethetimeofclopidogrelinterruption.Indeed,innormal
and high-responders patients, clopidogrel was withdrawn
5 days before surgery, due to the expected higher risk of
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Figure 1: Platelet aggregation assessed by the point-of-care
Multiplate analyzer (AU: arbitrary aggregation units (AUs)
that are plotted against time: AU·min). According to the AU·min
value, the following groups were identiﬁed: enhanced responders
(≤188AU·min), low responders (≥468AU·min), and normal
responders (189 to 467AU·min). Time of clopidogrel interruption
before surgery was deﬁned according to the Au-min value.
bleeding than thrombosis. On the contrary, in the low-res-
ponders patients, clopidogrel was withdrawn the day of the
intervention, due to the expected higher tisk of thrombosis
than bleeding [11]( Figure 1). It was restarted with a loading
dose of 600mg as soon as possible after surgery, according
to the clinicians discretion and patients’ conditions [12]. The
use of aspirin was decided by the surgeon.
2.4. Avantgarde Carbostent. The coronary system Avant-
garde Carbostent consists of a stent made of L605 cobalt-
chromium alloy (stellite 25) with a strut thickness of 70µm
or 80µm (for diameter ≥3.0mm) that is integrally covered
with i-Carboﬁlm. This second generation extremely thin
(≤0.3µm) coating is made of pure carbon atoms, which pro-
vides superior bio-haemocompatibility, resulting in stent
thromboresistance [13].
2.5. Study Objective. The primary objective of the study was
the assessment of the clinical performance of the Avantgarde
Carbostent in patients undergoing undeferrable noncardiac
surgery. The following in-hospital and 1-month major ad-
verse cardiac events (MACEs) were analyzed: cardiac death,
nonfatal myocardial infarction, stent thrombosis, and major
bleeding. Myocardial infarction was deﬁned as the associ-
ation of ≥1 clinical and ≥1 biological criteria: acute-onset
chest pain and/or typical modiﬁcation on electrocardiogramThrombosis 3
Table 1: Type of noncardiac surgery according to the risk∗.
Number of patients (n = 42)
High-risk surgery 40
Abdominal 10
Vascular 23
Thoracic 7
Low-risk surgery 2
Urologic 1
Orthopedic 1
Revised cardiac risk index#
1r i s kf a c t o r 2( 5 % )
2 risk factors 33 (76.5%)
3 or more risk factors 8 (18.5%)
The risk was deﬁned according to Eagle et al. [9]. The revised cardiac risk
index was according to Lee et al. [8].
(ST- or T-wave modiﬁcation or new left bundle branch
block) and an increase in troponin >99th percentile of the
upper reference limit [14]. Stent thrombosis was classiﬁed
according to the deﬁnition proposed by the Academic Re-
search Consortium [14]. Major bleeding was deﬁned as in-
tracranial, intraocular, or retroperitoneal haemorrhage, clin-
ically overt blood loss resulting in a decrease in haemoglobin
of more than 3g/dL, any decrease in haemoglobin of more
than 4g/dL, or transfusion of 2 or more units of packed red
blood cells or whole blood [15].
2.6. Statistical Analysis. Continuous variables are presented
as mean ± 1 standard deviation or as median and interquar-
tile ranges when appropriate. Categorical variables were ana-
lyzed by Chi-square test.
3. Results
3.1. Patients Characteristics. Forty-two patients were includ-
ed into the current study. The type of noncardiac surgery
according to the risk is reported in Table 1. The clinical and
angiographic characteristics are depicted in Tables 2 and 3.
The indication for myocardial revascularization was class Ia
in 35 (83%) patients and class IIa in 7 (17%) patients. Sur-
gery was performed after 27 ± 9 (7–42) days from stent im-
plantation. Duration of DAPT was 22 ± 8 (6–41) days. Ac-
cording to the AU·min value, 43% of patients were enhanced
responders (≤188AU·min), 16.5% were low responders
(≥468AU·min), and 40.5% normal responders (189 to
467AU·min).
3.2.ProceduralCharacteristics. Angiographicsuccesswasob-
tained in all patients. More than 1 stent was implanted in
8 patients (19%). Direct stenting was performed in 15 pa-
tients (21%). Rotational atherectomy was performed in one
patient.GlycoproteinIIb/IIIainhibitorwasusedinonly1pa-
tient. Bivalirudin was used in 11 (25.6%) patients. Six (14%)
patients had 2 or more stents. Distribution of stent diameter
is represented in Figure 2. Total stent length ≥ 25mm was
Table 2: Clinical characteristics of the enrolled patients.
Patients (n = 42)
Age, yrs (mean ± SD) 73 ± 9
Male (%) 33 (79%)
BMI (kg/m2)2 6 ± 3
Symptoms
Stable angina 29 (69%)
Unstable angina 13 (31%)
Diabetes mellitus 13 (31%)
Chronic kidney disease 18 (42%)
Hypertension (%) 32 (76%)
Current smoker (%) 9 (21.5%)
Prior MI (%) 14 (33%)
Prior PCI (%) 4 (9.5%)
Prior CABG (%) 6 (16%)
LVEF, % (mean ± SD) 49 ± 9
Clopidogrel stopped  Clopidogrel stopped 
the day of surgery
High-responders Normal-responders Low-responders
5 days before surgery
     189–467 AU.min ≥468 AU.min ≤188 AU.min
Figure 2: Distribution of the stent diameter in the global popula-
tion.
observed in 16 (37%) patients. Multivessel stenting was per-
formed in 11 (31.5%) patients. Periprocedural myocardial
infarction occurred in 14 (32.5%) patients. The quantitative
coronary angiography characteristics are reported in Table 4.
3.3. Clinical Outcome. According to the residual platelet re-
activity,clopidogrelwasstoppedthedaybeforethesurgeryin
the 7 (16.5%) low-responders patients. In all the others, both
aspirin and clopidogrel administration were interrupted 5
days before the scheduled surgery. There was only one case
(2.4%; 95% conﬁdence interval: 0.01–13%) of MACE at 1
month. The patient had fatal acute anterior myocardial in-
farction 3 days after abdominal aortic aneurysm surgery and
12daysafterstentimplantation(Avantgarde3.0 ×25mm)in
the proximal left anterior descending artery. This patient was
aﬀected by chronic kidney disease and had periprocedural
myocardial infarction: due to the high residual platelet reac-
tivity, clopidogrel was discontinued the day before surgery.
No case of major bleeding in the postoperative phase was
observed.
4. Discussion
The current pilot study suggests that (1) the Avantgarde Car-
bostentmayrepresentapromisingnewstenttobeselectedin
PCI performed before undeferrable noncardiac surgery, and4 Thrombosis
Table 3: Angiographic characteristics of the enrolled patients.
Total population (n = 42)
Distribution of coronary artery disease 45
1-vessel 13 (29%)
2-vessel 13 (29%)
3-vessel 19 (42%)
Vessel treated 45
Left main 5 (11%)
LAD 23 (51%)
LCX 14 (31%)
RCA 3 (7%)
Lesion site 49
ostial 8 (16%)
proximal 20 (41%)
midvessel 17 (35%)
distal 4 (8%)
Lesion type 49
A 7 (14.5%)
B1 16 (32%)
B2 19 (39%)
C 7 (14.5%)
Bifurcation lesions 13 (30%)
Double stenting technique 5 (11.5%)
Chronic total occlusion 2 (4.5%)
Number of treated vessel/patient 1.1 ±0.5
Number of treated lesion/patient 1.2 ±0.7
LAD: left anterior descending artery; LCX: left circumﬂex artery; RCA: right
coronary artery.
(2) the Multiplate analyzer point-of-care platelet function
testing may be used to guide the time of clopidogrel admin-
istration interruption.
Kaluza et al. ﬁrstly reported that patients undergoing
noncardiacsurgerywithin6weeksofBMSimplantationhave
a 20% death rate; the risk is almost limited to those pa-
tients treated in the ﬁrst 2 weeks [2]. The majority of deaths
were caused by acute myocardial infarction and stent throm-
bosis. Other experiences reported a MACE rate ranging
from 3.9% to 86% [3–5, 16–18]. Noncardiac surgery after
stent implantation remains a delicate balance between the
deleterious stent thrombosis with myocardial infarction, the
potential risk of increased intra- and postoperative blood
loss, hypercoagulability attributable to the surgical trauma,
andtheperioperativestress[2,3,16,19].Noncardiacsurgery
increases the risk of stent thrombosis, especially when the
procedure is performed early after stent implantation, likely
because stents are not yet endothelialized, because DAPT is
often discontinued in the periprocedural period and because
surgery creates a prothrombotic state [20, 21]. The stress
response to major surgery includes sympathetic activation
promotingshearstressonarterialplaques,enhancedvascular
reactivity inducing vasospasm, reduced ﬁbrinolytic activ-
ity, platelet activation, and hypercoagulability. This concern
Table 4: Quantitative coronary angiography and procedural char-
acteristics of the enrolled patients.
Total population (n = 42)
Diameter stenosis, %
Pre 81 ± 9
Post 2 ± 2
Reference vessel diameter, mm
Pre 3.2 ± 0.6
Post 3.4 ± 0.6
Minimal lumen diameter, mm
Pre 0.53 ± 0.43
Post 3.3 ± 0.5
Lesion length, mm 16 ± 5
Maximum balloon-to-artery ratio 1.19 ± 0.22
Postdilatation (semicompliant
balloon) 45 (83%)
Final pressure (atmospheres) 20 ± 5
Total stent length/patient, mm 24 ± 11
highlighted the importance of (1) limit revascularization
only to high-risk patients [22–24] and (2) delaying surgery
when possible and continuing DAPT in the perioperative
period when surgery is not delayed [12]. When revascular-
ization is required, PCI with eventual BMS is recommended
[1].
4.1. Time of Clopidogrel Discontinuation. T h e r ei sag e n e r a l
agreement that premature DAPT discontinuation represents
themajorcauseofin-stentthrombosis,leadingtomyocardial
infarction or even death. Indeed the MACE rate was very low
in patients operated on who continued DAPT [5, 17]. On
the other hand, the incidence of bleeding is high when DAPT
is continued [25]. The ACC/AHA guidelines recommend to
delay surgery until after the time window required for DAPT,
30-day for BMS and 1 year for DES [1]. However, the 30 days
DAPT may represent an unacceptable delay for some pa-
tient scheduled for undeferrable noncardiac surgery. In the
present pilot study, we observed that the Multiplate analyzer
point-of-care platelet function testing may be used to guide
the time of clopidogrel administration interruption. Indeed,
in low-responders patients clopidogrel might be stopped the
day of the surgery. An alternative strategy has been proposed
by Savonitto et al. in 30 patients with a recently implanted
drug eluting stent (1–12 months) and undergoing unde-
ferrablenoncardiacsurgery.Thisapproach,named“bridging
strategy”,includestiroﬁban(anintravenousshort-actinggly-
coprotein IIb/IIIa receptor blocker) in the perioperative
period in order to temporary replace oral clopidogrel, inter-
rupted 5 days before the intervention [26]. No adverse car-
diac events during the index hospitalization were observed.
Onthecontrary,therewas1caseofmajorbleedingand5cas-
esofminorbleedings.Finally,ticagrelor,duetoitsshorthalf-
life and the observed less surgery-related bleeding events,
may represent a valuable clinical alternative in this subset
of patients [27]. Ticagrelor, indeed, is the ﬁrst reversiblyThrombosis 5
binding oral P2Y12 receptor antagonist that blocks ADP-in-
ducedplateletaggregationandexhibitsrapidonsetandoﬀset
of eﬀect, which closely follow drug exposure levels.
4.2. Stent Platform. New stent types, allowing more rapid re-
endothelialization, may minimize the risk of stent thrombo-
sis and therefore may represent an alternative strategy in this
high-risk population. The Avantgarde Cardoﬁlm has some
potentially favorable characteristics, including (1) a reduced
strut thickness (70–80µ), (2) the Co-Cr alloy, and (3) the i-
Carboﬁlm coating. Haemocompatibility is one the main req-
uisites of materials used in the making of coronary stents. As
compared to the endothelium, the natural vascular surface,
all the artiﬁcial surfaces activate platelets and coagulation
plasmatic factors. In order to improve blood compatibility,
surface treatments are performed on biomaterials. One of
these treatments consists of coating the material made of
pyrolyticcarbon.Thisisanartiﬁcialmaterialmadeofcarbon
microcrystals with a high-density turbostratic structure. It
has been demonstrated that this Carboﬁlm coating shows
a lower thrombogenicity than the uncoated material, as it
induces minimal platelet adhesion and limits the activation
of the intrinsic pathway of coagulation [28]. In vitro studies
have shown a quick growth and attachment of endothelial
cells in the Carboﬁlm-coated samples [29]. In an in vivo op-
tical coherence tomography study enrolling 20 patients with
acute myocardial infarction treated by the Avantgarde Car-
bostent implantation, Prati et al. reported that observed a
quite complete stent struts coverage after only 3–7 days. The
stent level analysis, indeed, showed an overall percentage of
uncovered struts of 4.4% ± 3.4% (range 0.3–12.1%) [30].
The coronary stents belonging to the Carbostent family have
been already tested in 3 studies [10–12], designed speciﬁcally
to evaluate the safety proﬁle of these devices in patients re-
ceivingaspirinalone(ANTARESandSIMPLE)orcomparing
the safety performances in patients receiving aspirin and thi-
enopyridine versus aspirin alone (SAFE). The results of these
3 clinical studies demonstrated the excellent safety proﬁle of
the Carbostent devices.
Antibody-coated stents that can attract endothelial pro-
genitor cells have been also proposed. Piscione et al. recently
reported a pilot study of 30 patients treated by the Genous
“prohealing” stent, followed by a short-term DAPT, before
undeferrable urgent of live-saving noncardiac surgery [6].
The Genous bioengineered R stent (OrbusNeich medical
Technologies, Fort Lauderdale, Fla, USA) is coated by anti-
hCD34. This stent should lead to a rapid vessel and strut
healing, due to its properties of capturing circulating CD-
34+, progenitor cells to the luminal stent struts [31]. Anti-
platelet therapy was stopped after 12.2 ± 3.9 days after stent
implantation. Noncardiac surgery was performed 10 to 22
daysafterstenting (average17.2±3.9 days). Undelayable sur-
gical procedures were high risk in 67% of patients. No pa-
tients suﬀered from MACE or bleeding in the perioperative
period.
4.3. Study Limitations. The small sample size and the lack of
acontrolgrouprepresentthemajorlimitationsofthepresent
registry.Indeed,thisisapilotstudydesignedtotestthehypo-
thesis of the advantages of Avantgarde Carbostent implanta-
tion in this high-risk population. Furthermore, the safety of
clopidogrel interruption guided by the Multiplate analyzer
point-of-care platelet function testing should be tested in a
larger population.
5. Conclusions
The present pilot study suggests that the Avantgarde Car-
bostent may represent a valuable alternative to treat patients
with severe coronary artery disease and undelayable noncar-
diacsurgery.Furtherstudiesareneededtoconﬁrmthisresult
in a larger population.
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